Cayman 2,3,5-Triacetyluridine

2’,3’,5’-Triacetyluridine is a prodrug of uridine (Item No. ). It is more lipid soluble than uridine and resistant to degradation by uridine phosphorylase. It is cleaved by plasma esterases in vivo to release uridine. 2’,3’,5’-Triacetyluridine (6% in the diet) decreases neurodegeneration in the piriform cortex and striatum, as well as reduces the amount of huntingtin-positive aggregates and increases BDNF protein levels in the piriform cortex in a transgenic mouse model of Huntington’s disease. It also improves rotarod performance and increases survival in transgenic mouse models of Huntington’s disease. 2’,3’,5’-Triacetyluridine reverses toxicity and increases survival in a mouse model of dihydropyrimidine dehydrogenase (DPD) deficiency-induced 5-fluorouracil (5-FU; Item No. ) overdose when used at a concentration of 2,000 mg/kg three times per day beginning within 24 hours of 5-FU administration. Formulations containing 2’,3’,5’-triacetyluridine have been used in the treatment of hereditary orotic aciduria and of overdose or life-threatening toxicity due to flurouracil or capecitabine.

WARNING This product is not for human or veterinary use.